key: cord-0905066-ddymt74i
authors: Singh, Natesh; Villoutreix, Bruno O.
title: Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: lessons from the pandemic and preparing for future health crises
date: 2021-04-26
journal: Comput Struct Biotechnol J
DOI: 10.1016/j.csbj.2021.04.059
sha: f1cbdae027e312002582994ada5a683636184073
doc_id: 905066
cord_uid: ddymt74i

There is an urgent need to identify new therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. This pandemic has thus spurred intensive research in most scientific areas and in a short period of time, several vaccines have been developed. But, while the race to find vaccines for COVID-19 has dominated the headlines, other types of therapeutic agents are being developed. In this mini-review, we report several databases and online tools that could assist the discovery of anti-SARS-CoV-2 small chemical compounds and peptides. We then give examples of studies that combined in silico and in vitro screening, either for drug repositioning purposes or to search for novel bioactive compounds. Finally, we question the overall lack of discussion and plan observed in academic research in many countries during this crisis and suggest that there is room for improvement.

Since Spike, an oligomeric transmembrane protein, can be cleaved and further activated by several enzymes [7, 8] , including the host surface serine protease, TMPRSS2 [3] ( Figure 1 ). The severity of the host response depends on numerous factors, including an innate response to viral recognition [9, 10] . If the antiviral response is delayed or inhibited, viral proliferation can lead to the large-scale recruitment of neutrophils and monocyte-macrophages to the lungs, creating a hyper-inflammatory environment [10] . It has been found, in some COVID-19 patients, that there is an intense release of pro-inflammatory cytokines, i.e., cytokine storm (CS) [11] [12] [13] [14] , and in some patients, rapid progression to Acute Respiratory Distress Syndrome can occur [15] [16] [17] .

Many different strategies can be used to identify disease prevention drugs and/or treatments. In the present context, considering the virus life cycle, one may aim at drugs acting at different stages of the infection (e.g., entry, replication, and dissemination…) [7, [18] [19] [20] [21] [22] [23] [24] . The drugs could be small chemical compounds and (stapled) peptides [21, [25] [26] [27] [28] [29] [30] [31] [32] , therapeutic proteins including antibodies or nanobodies [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , vaccines [46, 47] and cells [48] [49] [50] . These drugs could interfere with the functioning of viral macromolecules and/or with the host proteins and/or complex not fully understood molecular mechanisms and pathways (e.g., many cationic amphiphilic drugs act on specific targets but also on endocytosis [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] .

As in all drug discovery project involving small molecules (but also often for other types of therapeutic agents), there are many ways to prioritize targets depending on the goal ( ( Figure 1 ). Clearly, many other host proteins and protein-protein interactions can also be considered (e.g., possibly the CD147-Spike interaction and a few hundred others).

As mentioned above, developing (antiviral) drugs (from small molecules to vaccines) is extremely challenging [91, 92] and thus, selecting a strategy is obviously critical (e.g., designing a novel compound, a peptide, targeting the enzymes catalytic sites or exosites including allosteric sites…use approved drugs, virtual compounds, etc.). For example, while it might seem easier to identify small molecules inhibiting the catalytic site of viral enzymes as compared to finding inhibitors of protein-protein interactions, mutations in the viral genome can lead to amino acid changes in catalytic centers and possibly drug resistance, thereby making the compound totally or partially ineffective in a short period of time [93, 94] . This situation is less likely at protein-protein interaction (PPI) interfaces [94] [95] [96] [97] . Also, covalent binders [98] can be of interest, definitively to act on viral enzymes [99] but also to block PPIs as seen in the field of cancer [100] . Further and obviously, to find drugs, it is necessary to understand as much as possible the molecular mechanisms at play, and thus, important biochemical and biological studies have to be performed with associated efficient in vitro assays and animal models. These might be very difficult for complex diseases in general and definitively for this virus [101, 102] .

Thus, each drug discovery strategy, each selection of targets or pathways, has strengths and weaknesses (e.g., in infectious diseases it could be interesting to target the host proteins to reduce resistance, in oncology the selection of the right therapeutic agents has to be consider early in the process if for instance the drug needs to penetrate some tumors, in such a case, some biologics are not appropriate). Along the same line of reasoning, it is well-known that time factor and cost have to be considered. The search for drug candidates can take years (e.g., the design of novel antiviral compounds starting from the screening of a large compound collection with various optimization steps including Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties) while other approaches are in general quicker such as drug repurposing or repositioning (e.g., [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] ). Vaccine and antibody development can also be a long and difficult process with potential additional problems for microorganisms with moderate and high mutation rates not even mentioning, manufacturing, shipping, and storage problems and overall public acceptance [115, 116] when it comes to administration to billions of people. What is also obvious from the above is that to design and find treatments, a large number of skills and methodologies are required. Altogether, to face a pandemic (or a global health) crisis, it would seem, at least in academia and at a national level if easier to implement at first, that all the interested scientists should be involved in the process, and that a roadmap should be collectively decided, avoiding as much as possible silo mentality, silo working and related devastating human behaviors commonly seen during a crisis.

In this mini-review, we are interested in computational methods that can assist the socalled early stages of drug discovery. We will focus on tools dedicated to the identification of low molecular weight drug candidates. First, we will briefly introduce some of the computational/data science approaches that can be used to gain insights to search for drug candidates. This first section will also present several online resources and databases that have been used or developed to study SARS-CoV-2. Readers specifically interested in computational approaches that facilitate the development of vaccines or antibodies can find many recent articles and reviews on the topic (e.g., [92, [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] . Then, we will give examples of studies that combined in silico and experimental approaches to identify putative chemical probes.

Finally, we discuss the way research, essentially in academia, has been organized in several countries and suggest possible avenues for improvement.

In modern days, many different in silico approaches can be used to assist the design of a drug candidate or drug, from data (e.g., text and image) mining (e.g., annotated drug databases, approaches and pharmacophore-based methods [191] [192] [193] [194] . Quantitative structure-activity relationship (QSAR, employing various types of machine learning and artificial intelligence algorithms, but these approaches can also be used in docking, binding pocket prediction, scoring….) methods represent other types of powerful ligand-based techniques [107, 127, 132, 137, 138, 142, 195] . SBVS involves molecular docking of chemical libraries into one or several binding pockets, followed by qualitative and quantitative estimation of the docking poses [141, 196] . With such approaches, it is possible to target a catalytic site, an allosteric site, or a pocket present at macromolecular interfaces [80, 81, 151, 197] . The most appropriate pockets can be selected, either for docking or de novo compound generation taking into account properties of the cavity [198] [199] [200] [201] [202] . In most cases, flexibility of these putative targets/pockets have to be investigated [147, 148, 156] . The compound collections can be, like in LBVS studies, approved, investigational or experimental molecules [203] , purchasable compounds and virtual compounds [204] , covalent binders [130, 205] or small fragments [206] . Different types of scoring functions can then be used to select the molecules for experimental assays [155, 157, 160, [207] [208] [209] [210] [211] . LBVS and SBVS can be combined if the right data are available [134] . Then, as new knowledge is being reported, various types of data mining approaches and workflows can be developed and used [212] . It becomes possible to, for instance, develop statistical predictive models based on experimental screening data so as to predict the bioactivity of a novel compound [213] while, as the 3D structures of many potential targets are now known, SBVS can be performed on different binding pockets with, for instance, ultra-large compound collections [150] .

During the Covid-19 pandemic, in wet and dry laboratories alike, numerous projects were initiated and supported by short-term research grants. In the field of computational and data sciences, a tremendous amount of work has been accomplished (e.g., online tools, open databases) in a short period of time [152] . These developments are of high interest as these approaches can help to design chemical probes, drug candidates, therapeutic peptides or proteins and generate new ideas [214] . Further, if these tools and databases are properly maintained (thus the question about short-term funding), they should be also essential for future research projects and for teaching purposes. What was also impressive, during this crisis, was the amount of computer power available. Most computer groups could have access to super computers and the difficulties were elsewhere, the lack of funding to employ scientists with a proper training in both, computer/data sciences and drug discovery (small molecules and/or biologics).

We have collected several of these online tools/databases, especially those dedicated to drug design (see supplement Table 1 ). Yet, some of these are not directly concerned by drug design per se but can be used to gain knowledge about SARS-CoV-2, from genome analysis, visualization tools for epidemiological studies, approaches to study potential therapeutic targets, or to map variants on the 3D structures of the viral proteins (e.g., in binding pockets, in neutralizing antibody binding regions, to design vaccines that would still be effective against treatments using different drug discovery tools. This figure was inspired by the study reported here [215] .

Many different types of computations have been carried out and combined with experimental approaches to search for anti-SARS-CoV-2 molecules. As thousands of articles have been reported, it is only possible to mention some here. For example, we will not cover the following studies to save space [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] .

Jin et al. identified a mechanism-based peptidomimetic inhibitor N3 1 ( Figure 2 ) using computer-aided drug design (CADD) techniques [228] . Mpro in complex with these inhibitors, which revealed that the aldehyde groups of 10 and 11

are covalently attached to C145 of Mpro.

In another study [231] , a consensus docking-based virtual screening protocol was applied to ~ subpopulations coupled to its in vivo pharmacokinetics, which revealed that Baricitinib inhibited signaling of cytokines implicated in COVID-19 [237, 238] . In addition, the inhibitory effects of baricitinib were also evaluated on human numb-associated kinase (hNAK) members, such as AAK1, BIKE, and GAK, for which it showed affinities in the nanomolar range (8.2 nM, 20 nM, and 120 nM, respectively). The NAK enzymes are believed to facilitate the propagation of coronavirus in epithelial cells [234, 239, 240] . Baricitinib triggered inhibition of NAKs led to reduced viral infectivity in human primary liver spheroids [235, 237] . Besides the use of AI in drug discovery, it was recently applied to improve the diagnosis or early warning signs of COVID-19 infection [241] . For instance, researchers at King's College London, in collaboration with Massachusetts General Hospital, designed the COVID Symptom

Tracker, developed an AI-based smartphone app that monitors viral transmission and symptoms [242] . This tool identified the importance of anosmia as an early warning symptom. The AIpowered NHSX contact tracing app warns users about viral exposure and so dramatically reduces transmission rates. Alerts are triggered when users self-report symptoms or test positive while respecting anonymity. [249] .

In a recent and innovative study, Cao et al. targeted the interaction between the SARS-CoV-2 spike protein and the human ACE2 using de novo design approaches [250] . Computergenerated scaffolds were built around an ACE2 helix that interacts with the spike receptorbinding domain (RBD) or docked against the RBD to identify new binding modes, and subsequently, their amino acid sequences were designed to optimize the target binding, folding, and stability. Ten designed miniprotein inhibitors were found to be binding to the RBD and It is important to note that some of these molecules (e.g., Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin) could be nonspecific promiscuous compounds (see [229] ). 

Numerous problems about the present Covid-19 crisis have been reported by different groups

[91, [251] [252] [253] . We add below some of our observations.

Since the beginning of this crisis, hundreds/thousands of scientists in academia (e.g., in Europe) have been puzzled by the lack of a roadmap with a clear, collectively planned definition of research priorities and distribution of tasks. As a result, many projects got started in uncoordinated ways, squandering scare resources. Many researchers, supposed to be working towards the same objective, often on the same campus, could not share information nor (precompetitive) data because nobody was clearly in charge. These, most likely, led to many missed opportunities. Along the same line of reasoning, if we take the specific case of drug repositioning, in several countries in Europe, no strategies were discussed among the teams and the combination of in silico and in vitro approaches insufficiently used (or not used at all). This would have been important as compounds missed in vitro could have been identified in silico and vice versa. Definitively the lack of discussions with decision makers and the fact in silico drug designer teams were essentially ignored during this crisis is frightening.

Another point in many countries (not directly related to Covid-19 but) and at least in academic research, has been the realization that for over 20 years, financial supports for drug discovery have been very limited. Further, drug discovery skills are often not considered in academia and thus, the scientists working in this field have usually even less chance to move on with their careers [254] . During this crisis, it was surprising to have to spend so many precious hours in writing low success-rate grants while thousands of people were dying every day. Changes seem needed.

Explanations about drug discovery to the general population, the strengths and weaknesses of each approach (silico, vitro, animal models) and about the therapeutic agents have been essentially lacking.

Rigidity versus agility and so many unclear entry points. Delays and unnecessary bureaucracy are well-known in academia, but scientists have been told, for several decades already, that processes were going to be improved (less bureaucracy, encouraging teamwork, self-organization…). Also, in many countries (e.g., in Europe), millions of euros were spent in a myriad of fragmented projects but definitively not enough were dedicated to the development of in vitro screening platforms (i.e., the cost of developing such platforms to quickly test hypotheses is negligible as compared to the social and economic turmoil caused by the pandemic). Animal model platforms were even less available to drug hunters, even more so for computer teams. The process, if any, to test a candidate molecule with the help of an experimental platform was thus very complex with no clear entry point. This suggests that many interesting compounds (or drug combinations) could not be explored in a timely manner. Along the same line, the procedure to initiate (or to build on the results of) clinical trials, at least for approved drugs, was also very frustrating and many interesting drugs or drug combinations could not be explored in some countries because of unnecessary bureaucracy.

Hope for the future. Definitively, we believe that these observations call for changes in the management of research in many countries. With regard to academic drug discovery, important efforts have been done, for example in the USA, with the creation of the Academic Drug Discovery Consortium or dynamic maps to develop small molecules or biologics proposed by the National Center for Advancing Translational Sciences [255] [256] [257] , in UK [258, 259] or in Sweden [260] , to mention only a few. Of course, we are all aware that academic drug discovery is challenging and difficult to organize [261] . Yet, instead of a fragmented and very costly academic drug discovery research as presently operated in many countries, it should be possible to develop true interdisciplinary (including computational groups), coordinated and agile drug discovery networks that still recognize scientists and skills along the value chain.

The COVID-19 pandemic has severely affected the everyday life of humans [262] . In this minireview, we first reported some online in silico approaches and databases that can assist the study of SARS-CoV-2. Although the race to find vaccines has been dominating the headlines, it is important to note that the search for other types of anti-viral agents are important to develop.

Overall, computational approaches have assisted numerous projects and in several cases proposed interesting compounds that have been validated in vitro. When time is a critical factor, combined in silico and in vitro repurposing approaches can indeed be a possible avenue but efforts on the prediction of the potential benefit of drug combination will be needed. In parallel, screening large (and high quality) compound collections (including virtual small chemical compounds and peptides) can be extremely valuable but of course the process is more time consuming. Novel, more efficient tools to predict ADMET properties and to predict the best possible targets or pathways are still needed and so are strategies that can help selecting the best treatments for a given population. These challenges do not only apply to infectious diseases but to most disease conditions. Besides assisting the identification of putative drugs, computational approaches combined with molecular biology and medicine and with biophysical methods helped to improve our understanding of several mechanisms involved in the virus life cycle, in some cases, at the atomic level. Hit-to-lead optimization of the discovered chemotypes using various in silico including multi-parameter optimization strategies and medicinal chemistry skills are ongoing and may lead to superior ligands that could be brought to the clinics in a near future.

But to be prepared to face future global health challenges, we believe that establishing integrated academic in silico-in vitro-in vivo early drug discovery networks has to become a priority in many countries. At present, academic drug discovery research is often fragmented, while collaborations between the public and private sectors remain most of the time, in many countries, wishful thinking. Breaking silos is also going to be a major challenge for the years to come as so many skills and technologies/knowledge are needed to cost-effectively discover new drug candidates. Are we prepared for the next global health crisis (plans, structures and resources)? For the time being, the answer is no. The scientific community has done outstanding work during this crisis but the top-down management seen in many (nonprofit) organizations and in many countries has often stifled researchers' creativity and destroyed engagement.

We apologize for not being able to reference all the in silico studies in this review, this is not only due to space limitation but also to the fact that thousands of articles using in silico approaches have been reported these last several months and that it is impossible to review all in a mini-review. Bergström F, Lindmark B (2019) Accelerated drug discovery by rapid candidate drug identification. Drug discovery today. 24:1237-41.

Canning P, Birchall K, Kettleborough CA, Merritt A, Coombs PJ (2020) Fragmentbased target screening as an empirical approach to prioritising targets: a case study on antibacterials. Drug discovery today. 73.

Duarte Y, Márquez-Miranda V, Miossec MJ, González-Nilo F (2019) Integration of target discovery, drug discovery and drug delivery: A review on computational strategies. Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology. 11:e1554. 74.

Wilkinson IVL, Terstappen GC, Russell AJ (2020) Combining experimental strategies for successful target deconvolution. Drug discovery today. 75.

Cavasotto CN, Phatak SS (2009) Homology modeling in drug discovery: current trends and applications. Drug discovery today. 14:676-83. 

CoV-2 discovery: lessons from the pandemic and preparing for future health crises Iran [55] 

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Mechanisms of SARS-CoV-2 Transmission and Pathogenesis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The Architecture of SARS-CoV-2 Transcriptome

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat origin

COVID-19: Drug Targets and Potential Treatments

Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin

A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

Immunotherapeutic implications of IL-6 blockade for cytokine storm

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection

Acute respiratory distress syndrome

Cytokine release syndrome in severe COVID-19

Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials

Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases

The resurgence of covalent drugs

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains. Infectious diseases and therapy

A review on drug repurposing applicable to COVID-19

Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? Frontiers in pharmacology

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study

COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays

Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital health

Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention

What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?

Artificial intelligence approach fighting COVID-19 with repurposing drugs

An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv : the preprint server for biology

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human

Transforming vaccine development

Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug metabolism and pharmacokinetics

The SARS-CoV-2 Vaccine Pipeline: an Overview. Current tropical medicine reports

Keeping track of the SARS-CoV-2 vaccine pipeline

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochemical and biophysical research communications

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

MAbTope: A Method for Improved Epitope Mapping

Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. The journal of physical chemistry letters

SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional Features, and Implications for Drug/Vaccine Designs

COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning

In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives. Advanced drug delivery reviews

Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert review of vaccines

Artificial intelligence in the early stages of drug discovery. Archives of biochemistry and biophysics

COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine

Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs

Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors

Cheminformatics in Natural Product-based Drug Discovery. Molecular informatics

New Perspectives of Machine Learning in Drug Discovery

Drug2ways: Reasoning over causal paths in biological networks for drug discovery

Docking-based identification of small-molecule binding sites at protein-protein interfaces. Computational and structural biotechnology journal

Selecting machine-learning scoring functions for structure-based virtual screening. Drug discovery today Technologies

Towards gaining sight of multiscale events: utilizing network models and normal modes in hybrid methods. Current opinion in structural biology

Accuracy or novelty: what can we gain from target-specific machine-learning-based scoring functions in virtual screening?

Race to arsenal COVID-19 therapeutics: Current alarming status and future directions

Analysis of protein missense alterations by combining sequence-and structure-based methods. Molecular genetics & genomic medicine

Fast Rescoring Protocols to Improve the Performance of Structure-Based Virtual Screening Performed on Protein-Protein Interfaces

The Art of Compiling Protein Binding Site Ensembles

Tools for in silico target fishing

The challenges involved in modeling toxicity data in silico: a review

From in silico target prediction to multi-target drug design: current databases, methods and applications

Computational Approaches in Antibody-drug Conjugate Optimization for Targeted Cancer Therapy. Current topics in medicinal chemistry

Coarse-grained (hybrid) integrative modeling of biomolecular interactions. Computational and structural biotechnology journal

Docking approaches for modeling multi-molecular assemblies. Current opinion in structural biology

Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning

Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches

Drug repurposing approach to fight COVID-19

Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal. iScience

Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated

Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering

The Pharmacophore Concept and Its Applications in Computer-Aided Drug Design. Progress in the chemistry of organic natural products

Similarity searching using 2D structural fingerprints

Deep learning

Key Topics in Molecular Docking for Drug Design. International journal of molecular sciences

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Approaching Target Selectivity by De Novo Drug Design

De novo Molecular Design with Generative Long Shortterm Memory

A Review on Applications of Computational Methods in Drug Screening and Design

Advances in de Novo Drug Design: From Conventional to Machine Learning Methods. International journal of molecular sciences

Virtual Screening FDA Approved Drugs against Multiple Targets of SARS-CoV-2. Clinical and translational science

Using DrugBank for In Silico Drug Exploration and Discovery. Current protocols in bioinformatics

ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery

Covalent Docking in Drug Discovery: Scope and Limitations

Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications. The AAPS journal

New machine learning and physics-based scoring functions for drug discovery

High-Throughput Docking Using Quantum Mechanical Scoring

silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking. Molecular informatics

Application of MM-PBSA Methods in Virtual Screening

ASFP (Artificial Intelligence based Scoring Function Platform): a web server for the development of customized scoring functions

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research. bioRxiv : the preprint server for biology

REDIAL-2020: A Suite of Machine Learning Models to Estimate Anti-SARS-CoV-2 Activities. ChemRxiv : the preprint server for chemistry

Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace

Artificial intelligence for COVID-19 drug discovery and vaccine development

Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research

Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19

Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease

Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro

Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases

Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. Plant foods for human nutrition

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19

QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2

Bepridil is potent against SARS-CoV-2 in vitro

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. bioRxiv : the preprint server for biology

Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase. The journal of physical chemistry letters

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Can artificial intelligence identify effective COVID-19 therapies?

Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Early events during human coronavirus OC43 entry to the cell

The Emerging Role of Artificial Intelligence in the Fight Against COVID-19

Real-time tracking of self-reported symptoms to predict potential COVID-19

Furin: A Potential Therapeutic Target for COVID-19. iScience

Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2. bioRxiv : the preprint server for biology

Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay

OliveNet™: a comprehensive library of compounds from Olea europaea. Database : the journal of biological databases and curation

Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19. bioRxiv : the preprint server for biology

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Antimicrobial agents and chemotherapy

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals

Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions. Drug discovery today

Academic leadership: (with)holding the keys to translational medicine? Nature medicine

Bringing together the academic drug discovery community

A dynamic map for learning, communicating, navigating and improving therapeutic development

Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development

Rethinking 'academic' drug discovery: the Manchester Institute perspective. Drug discovery today

Academic drug discovery within the United Kingdom: a reassessment

Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab

Challenges with risk mitigation in academic drug discovery: finding the best solution

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global health

RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences

Coronavirus3D: 3D structural visualization of COVID-19 genomic divergence

CoV3D: a database of high resolution coronavirus protein structures

SWISS-MODEL: homology modelling of protein structures and complexes

The European Bioinformatics Institute: empowering cooperation in response to a global health crisis

SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Scientific data

PubChem in 2021: new data content and improved web interfaces

PROMISCUOUS 2.0: a resource for drug-repositioning

DrugBank 5.0: a major update to the DrugBank database

DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses

Discovery and development of safe-in-man broad-spectrum antiviral agents

A Modelling Framework for Embedding-based Predictions for Compound-Viral Protein Activity

A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening

Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs

Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds

DockCoV2: a drug database against SARS-CoV-2

An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv : the preprint server for biology

Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking. International journal of molecular sciences

DrugCentral 2021 supports drug discovery and repositioning

Artificial intelligence for COVID-19 drug discovery and vaccine development

Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds

DRDOCK: A Drug Repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme. bioRxiv : the preprint server for biology

COVID-19 Docking Server: a meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19

Systemic In Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server

-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19

Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Scientific reports. 11:5543. 28. Labbé CM

MTiOpenScreen: a web server for structure-based virtual screening

Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets

MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm

A Chemographic Audit of anti-Coronavirus Structure-activity Information from Public Databases (ChEMBL). Molecular informatics

AIDrugApp: Artificial Intelligence-based Web-App for Virtual Screening of Inhibitors against SARS-COV-2

CoV-Seq, a New Tool for SARS-CoV-2 Genome Analysis and Visualization: Development and Usability Study

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

GISAID: Global initiative on sharing all influenza datafrom vision to reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Exploring the structural distribution of genetic variation in SARS-CoV-2 with the COVID-3D online resource

GESS: a database of global evaluation of SARS-CoV-2/hCoV-19 sequences

ViruSurf: an integrated database to investigate viral sequences

Interactome of SARS-CoV-2 / nCoV19 modulated host proteins with computationally predicted PPIs. Research square

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

) A Structure-Informed Atlas of Human-Virus Interactions

HISNAPI: a bioinformatic tool for dynamic hot spot analysis in nucleic acid-protein interface with a case study

SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets. Briefings in bioinformatics. 45. (2020) PDBe-KB: a community-driven resource for structural and functional annotations

COVID-KOP: Integrating Emerging COVID-19 Data with the ROBOKOP Database. ChemRxiv : the preprint server for chemistry

H2V: a database of human genes and proteins that respond to SARS-CoV-2, SARS-CoV, and MERS-CoV infection

CORDITE: The Curated CORona Drug InTERactions Database for SARS-CoV-2. iScience

A Web-Based Platform on Coronavirus Disease-19 to Maintain Predicted Diagnostic, Drug, and Vaccine Candidates. Monoclonal antibodies in immunodiagnosis and immunotherapy

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics

A Tool and a Web Portal to Extract Drug -Target Protein Associations from the CORD-19 Corpus of Scientific Publications on COVID-19. ChemRxiv : the preprint server for chemistry

LitCovid: an open database of COVID-19 literature

Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments. bioRxiv : the preprint server for biology

COVID-19 web server: an online daily monitoring server for comparative and cumulative epidemiological analysis

CRediT authorship contribution statement Natesh Singh: Formal analysis, Writing -original draft. Bruno Villoutreix: Conceptualization, Supervision, Writing -review & editing

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.